Study of Immunogenicity and Protective Efficacy of Live MDCK-derived Pandemic Influenza Vaccine

• Main Authors: Elena A Nechaeva (Author), Ryzhikov AB (Author), Pyankova OG (Author), Radaeva IF (Author), Pyankov OV (Author), Danilchenko NV (Author), Agafonov AP (Author), Kiseleva LV (Author), Larionova NV (Author), Rudenko LG (Author)
• Format: Book
• Published: Global Journal of Infectious Diseases and Clinical Research - Peertechz Publications, 2019-06-06.
• Subjects: Research Article
• Online Access: Connect to this object online.

<p>Background: The threat of pandemic A/H1N1 influenza is still a matter of considerable public concern. Influenza outbreak in 2009 underlined the importance of rapid production of a sufficient vaccine reserve for pandemic and interpandemic periods. One promising way to allay this concern is development of cell culture-derived live attenuated influenza vaccines (LAIV), because this technology makes it possible to produce a considerable amount of vaccine over a short period of time.</p><p>Objectives: The goal of this work was to study the immunogenic and protective properties of the Vector-Flu vaccine in animal models.</p><p>Methods: We have developed Vector-Flu, a live attenuated vaccine against pandemic influenza, based on the cold-adapted reassortant vaccine strain for LAIV, A/17/California/2009/38(H1N1), and produced in certified MDCK cells. The immunogenicity and protective efficacy of Vector-Flu vaccine were studied in ferrets and mice.</p><p>Results: A double immunization with the live MDCK-derived Vector-Flu influenza vaccine induced a high level of neutralizing antibodies in ferret serum both to the pandemic A/Chita/3/2009(H1N1) influenza virus strain, isolated in Russia, and to the pandemic A/California/7/2009(H1N1) strain. Intranasal immunization of mice induced levels of serum antibodies sufficient to protect them when aerosol-challenged with 100 infectious doses of A/Chita/3/2009(H1N1) strain. </p><p>Conclusion: Theoretical estimates of protective antibody levels necessary for protecting humans from the disease caused by pandemic A/H1N1(2009) influenza virus, and the experimental data from animal models (ferrets and mice), suggest that the Vector-Flu vaccine is able to protect humans after a single immunization.</p>